Skip to main content
. 2019 Apr 8;11(4):502. doi: 10.3390/cancers11040502

Figure 1.

Figure 1

Effects of CM37 on ovarian cancer (OC) sphere formation and stemness markers. (A) The chemical structure of CM37; (B) percent inhibition of aldehyde-dehydrogenase (ALDH) enzymatic activity by 20 µM CM37 measured in vitro for the different orthologues; (C) spheres derived from primary OC cells isolated from ascites fluid and treated with control or increasing doses of CM37 were photographed with an inverted microscope at 100× magnification. (D) Numbers of live cells growing as spheres were assessed by CCK-8 colorimetric assay in patient-derived OC cells. (E) Percentage of ALDH+ cells in untreated/or CM37-treated (500 nM–5 µM) patient-derived OC cells. (F) Percentage of ALDH+ cells in untreated/or CM37-treated (2.5–10 µM) OVCAR5 cells. (G) OVCAR5 cells were plated under low attachment conditions for six days; numbers of live cells were assessed by using the CCK8 colorimetric assay. (H) Relative expression of stem cell markers KLF4, Nanog, Oct4, Sox2 as measured by qRT-PCR in ALDH+ FACS-sorted OVCAR5 cells treated with CM37 (1 µM) for 24 h. Bars represent averages of triplicate measurements; **** corresponds to p < 0.0001; *** corresponds to p < 0.001.